The National Heart, Lung, and Blood Institute (NHLBI) awarded a $169,222 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Alabama at Birmingham (UAB) to identify and evaluate ancestry and sex-related pharmacogenomic and metabolomic signatures of variable response to oral anticoagulants (OACs), including warfarin and direct oral anticoagulants (DOACs). The 5-year grant, awarded on Sep 18, 2024, will support research to characterize pharmacokinetic and pharmacodynamic predictors of DOAC response, identify genetic and metabolomic biomarkers of OAC-related hemorrhage, and elucidate biological pathways underlying variable OAC response. UAB will leverage its expertise in bioinformatics, metabolomics, electronic medical record-based phenotyping, and clinical research to achieve these aims and lay the foundation for personalized anticoagulation therapy approaches.
Generated 3/4/25, 6:35 AM